The Journal of investigative dermatology
Cure8 research brief
Why This Matters
The study identifies blood gene-expression patterns linked to response to TNF-alpha inhibitors and highlights overlap between psoriasis and IBD, which could point to shared biomarkers or mechanisms relevant to treatment response across immune diseases.
Who Should Pay Attention
Researchers, clinicians interested in biomarkers/anti-TNF response, and translational scientists studying psoriasis–IBD biology
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This was a time-course peripheral blood transcriptome study in 86 plaque psoriasis patients treated with TNF-alpha inhibitors.
The authors identified thousands of drug-response genes and a co-expression “red” module enriched for inflammation and TNF-related pathways; high expression of the module’s hub gene TNFSF10 was associated with poorer treatment outcome.
Some genes showed early changes (by week 2) in responders but not non-responders, and several DRGs were shared between psoriasis and IBD. The study is an analysis of gene expression patterns (an observational molecular study), not a clinical trial testing efficacy.
It suggests candidate biomarkers and pathways linked to anti-TNF response that may be relevant to IBD because of shared genes, but it does not establish clinical utility or treatment recommendations.
Keep In Mind
This classification and note are based on the article abstract. The study reports molecular associations in a psoriasis cohort and does not establish clinical recommendations for IBD patients; further validation is needed.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationThe Journal of investigative dermatology
AuthorsZhijie Xia, Lunfei Liu, Tao Wang +14 more
InstitutionDepartment of Epidemiology, School of Public Health, Lianyungang Medical-Education Innovation and Research Center, Nanjing Medical University, Nanjing, China; Key Laboratory of Immunoregulation and Intervention for Major Chronic Diseases of Jiangsu Province, Nanjing, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 9, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
SickKids-led research uncovers new genetic cause of Crohn's disease | EurekAlert!
Scientists found BIRC3 gene changes that cause Crohn’s in some patients and showed those changes drive inflammation through the RIPK1/TNF pathway. That suggests a new, druggable pathway and may help predict who benefits...
Single-nuclei multiome-seq and modeling of intestinal cell types nominates regulatory mechanisms driving IBD genetic risk and anti-TNF nonresponse 2309915
People with IBD (including those on TNF inhibitors) may benefit from research that explains why some patients don’t respond to anti-TNF drugs and that points to new biologic targets. Understanding cell types and...
Discovery of BIRC3 gene variants in Crohn's disease yields a druggable pathway
This study identifies a specific genetic cause (BIRC3 variants) that drives inflammation through the RIPK1/TNF pathway and points to an existing drug target (RIPK1). If validated, the finding could help match patients to...